Predicting value of Her-2 and Topo Ⅱ on recurrence and metastasis of breast cancer after surgery
-
摘要: 目的:探讨拓扑异构酶Ⅱ(TopoⅡ)与人类表皮生长因子受体2(Her-2)对乳腺肿瘤术后转移复发预测价值。方法:选择2009-05-2012-05我院行手术治疗的200例乳腺肿瘤患者作为研究对象,收集乳腺肿瘤组织及癌旁组织,采用免疫组织化学染色检测Her-2、TopoⅡ表达;以患者转移复发作为观察指标,分析Her-2、TopoⅡ表达与乳腺肿瘤术后复发转移的关系。结果:乳腺肿瘤组织Her-2、TopoⅡ阳性表达率显著高于癌旁组织(P＜0.05),术后复发转移组(83例)Her-2、TopoⅡ阳性表达率显著高于未复发转移组(117例)(P＜0.05)。单因素分析显示,Ⅲ期患者转移复发率(66.7%或54/81)显著高于Ⅰ~Ⅱ期(22.4%或29/119)患者,Her-2表达阳性转移复发率显著高于Her-2表达阴性患者,TopoⅡ表达阳性转移复发率显著高于TopoⅡ表达阴性患者,各组间比较差异具有统计学意义(P＜0.05)。多因素分析显示,临床分期、Her-2、TopoⅡ表达是影响乳腺肿瘤术后转移复发的独立危险因素(均P＜0.05)。结论: 乳腺肿瘤术后转移复发患者Her-2、TopoⅡ表达显著升高,Her-2、TopoⅡ均可以作为乳腺肿瘤术后转移复发的预测指标。
-
关键词:
- 拓扑异构酶Ⅱ /
- 人类表皮生长因子受体2 /
- 乳腺肿瘤 /
- 手术治疗 /
- 转移复发
Abstract: Objective:To explore the predicting value of Her-2 and TopoⅡ on breast cancer after surgery. Method:A total of 200 cases of breast cancer patients from May 2009 to May 2012 were selected, the breast cancer tissue and adjacent tissue were colected, and the expression of Her-2 and TopoⅡ in tissues were detected by immunohistochemical staining. Recurrence and metastasis as observation index, the relationship between Her-2 and TopoⅡ and recurrence and metastasis of breast cancer after surgery was analyzed. Result:The positive expression rate of Her-2 and TopoⅡ in cancer tissues were significantly higher than those in adjacent tissues (P<0.05), and the positive expression rate of Her-2 and TopoⅡ in the recurrence and metastasis group were significantly higher[HK] -
-
[1] Jiagge E, Oppong JK, Bensenhaver J,et al.Breast Cancer and African Ancestry:Lessons Learned at the 10-Year Anniversary of the Ghana-Michigan Research Partnership and International Breast Registry[J]. J Glob Oncol,2016,2:302-310.
[2] 陈万青,郑荣寿.中国女性乳腺肿瘤发病死亡和生存状况[J].中国肿瘤临床,2015,53(13):668-674.
[3] Sinha P, Piccirillo JF1, Kallogjeri D,et al.The role of postoperative chemoradiation for oropharynx carcinoma:a critical appraisal of the published literature and National Comprehensive Cancer Network guidelines[J].Cancer,2015,121:1747-1754.
[4] Gralow JR, Barlow WE, Lew D,et al. A phase II study of docetaxel and vinorelbine plus filgrastim for HER-2 negative, stage IV breast cancer:SWOG S0102[J]. Breast Cancer Res Treat,2014,143:351-358.
[5] Kwon W, Jang JY, Chang YR,et al.Suggestions for improving perihilar cholangiocarcinoma staging based on an evaluation of the seventh edition AJCC system[J].J Gastrointest Surg,2015,19:666-674.
[6] Voutsas IF, Mahaira LG, Fotopoulou K,et al.Gamma-irradiation induces HER-2/neu overexpression in breast cancer cell lines and sensitivity to treatment with trastuzumab[J].Int J Radiat Biol,2013,89:319-325.
[7] Boulos F, Farra CG, Saad Aldin EM,et al.Changing frequency of equivocal HER-2/neu scores and factors predictive of negative HER 2/neu fluorescent in situ hybridisation in invasive carcinomas of the breast[J].J Clin Pathol,2014,67:204-209.
[8] Baric M, Kulic A, Sirotkovic-Skerlev M,et al.Circulating Her-2/neu extracellular domain in breast cancer patients-correlation with prognosis and clinicopathological parameters including steroid receptor, Her-2/neu receptor coexpression[J]. Pathol Oncol Res,2015,21:589-595.
[9] 叶新青,蒋奕,刘鹏,等.乳腺肿瘤蒽环类药物化疗疗效与TOPOⅡα、HER-2的关系[J].诊断病理学杂志,2015,22(1):38-40,44.
[10] Conley SJ, Baker TL, Burnett JP,et al.CRLX101, an investigational camptothecin-containing nanoparticle-drug conjugate, targets cancer stem cells and impedes resistance to antiangiogenic therapy in mouse models of breast cancer.[J].Breast Cancer Res Treat,2015,150:559-567.
[11] 马斌,杨乐,孙刚,等.磷酸肌醇3激酶/蛋白激酶B/哺乳动物雷帕霉素靶蛋白信号通路特异性抑制剂RAD001和LY294002对不同分子特征人乳腺肿瘤细胞增殖和凋亡的影响[J].中华实验外科杂志,2015,32(9):2143-2145.
[12] Tan S, Sun D, Lyu J,et al.Antiproliferative and apoptosis-inducing activities of novel naphthalimide-cyclam conjugates through dual topoisomerase (topo)Ⅰ/Ⅱ inhibition.[J].Bioorg Med Chem,2015,23:5672-5680.
-
计量
- 文章访问数: 226
- PDF下载数: 0
- 施引文献: 0
下载: